Regulators are formally adopting real-world evidence, when will health technology assessment?

By HEOR Staff Writer

March 13, 2023

Over the last year, we’ve made great progress towards this goal. In June 2022, NICE published our real-world evidence framework.

The EMA and the European Medicines Regulatory Network recently established the Data Analysis and Real World Interrogation Network (DARWIN EU®). Using the OMOP CDM, DARWIN EU® delivers real-world evidence from across Europe on diseases, populations and the use and performance of medicines. This enables EMA and other organisations in the European medicines regulatory network to use this data whenever needed throughout the lifecycle of a medicinal product.

A workshop hosted by Dr Ravinder Claire outlines 2 case studies:
1) Difficulties in health technology assessment agencies when assessing treatments for cancer with the uncertainty surrounding long-term projections for overall survival.
2) COVID-19 projects in collaboration with the University of Oxford, where data from the EHDEN network is used to assess the effectiveness of baricitinib, tocilizumab and remdesivir in a hospital setting.

Reference url

Recent Posts

Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy

By João L. Carapinha

October 21, 2025

The Novo Nordisk board changes involve a major restructuring, as the Novo Nordisk Foundation is revitalizing leadership ahead of a general meeting on November 14, 2025, where new directors will be elected. Key candidates include former CEO Lars Rebien Sørensen as chair and Cees de Jong as vice ch...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC

By João L. Carapinha

October 20, 2025

If you're searching for effective options in Keytruda lung cancer treatment, recent data shows pembrolizumab (Keytruda) significantly boosts survival rates in non-small cell lung cancer (NSCLC). In the KEYNOTE-671 trial, this immunotherapy combined with chemotherapy raised five-year overall survi...
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk Groups

By HEOR Staff Writer

October 17, 2025

Cabotegravir HIV prevention is now officially recommended in the UK for adults and young people at high risk of HIV who cannot take daily oral PrEP. What makes this approval so significant? For those unable to adhere to daily medication, cabotegravir provides a bi-monthly injectable alternative w...